公开(公告)号：US10729775B2

公开(公告)日：2020-08-04

申请号：US16021193

申请日：2018-06-28

Applicant: Novartis AG

Inventor： Jeremy Lee Baryza ,  Rohan Eric John Beckwith ,  Keith Bowman ,  Crystal Byers ,  Tanzina Fazal ,  Gabriel Grant Gamber ,  Cameron Chuck-munn Lee ,  Ritesh Bhanudasji Tichkule ,  Chandra Vargeese ,  Shuangxi Wang ,  Laura Ellen West ,  Thomas Zabawa ,  Junping Zhao

IPC: A61K47/18 ,  C12N15/113 ,  A61K47/22 ,  C07D213/79 ,  C07D317/24 ,  C07D317/28 ,  C07D205/04 ,  C07D295/096 ,  C07D213/69 ,  A61K9/127 ,  C07C217/58 ,  C07C217/60 ,  C07C217/62 ,  C07C219/22 ,  C07C219/28 ,  C07C229/12 ,  C07C235/46 ,  C07C237/08

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

公开(公告)号：US10647701B2

公开(公告)日：2020-05-12

申请号：US16532118

申请日：2019-08-05

Applicant: Novartis AG

Inventor： Rohan Eric John Beckwith ,  Simone Bonazzi ,  Artiom Cernijenko ,  Ritesh Bhanudasji Tichkule ,  Michael Scott Visser

IPC: C07D401/14 ,  A61K31/44 ,  C07D401/04 ,  C07D407/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D495/04 ,  C07D513/04 ,  A61P35/00

Abstract: The present disclosure provides a compound of Formula (I′): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1, R2, Rx, X1, n, n1, and q are as defined herein, and methods of making and using same.

公开(公告)号：US10124065B2

公开(公告)日：2018-11-13

申请号：US14779939

申请日：2014-03-06

Applicant: Novartis AG

Inventor： Jeremy Lee Baryza ,  Rohan Eric John Beckwith ,  Keith Bowman ,  Crystal Byers ,  Tanzina Fazal ,  Gabriel Grant Gamber ,  Cameron Chuck-Munn Lee ,  Ritesh Bhanudasji Tichkule ,  Chandra Vargeese ,  Shuangxi Wang ,  Laura West ,  Thomas Zabawa ,  Junping Zhao

IPC: C07C211/00 ,  A61K9/00 ,  C07C217/00 ,  A61K47/22 ,  A61K47/18 ,  C07C217/58 ,  C07C219/06 ,  C07C229/12 ,  C07D317/28 ,  C07D295/096 ,  A61K9/127 ,  A61K9/51 ,  A61K31/713 ,  A61K38/22 ,  C07C229/14 ,  C07C235/42 ,  C07D205/04 ,  C07D213/69 ,  C07D213/79 ,  C12N15/113 ,  A61K48/00

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

公开(公告)号：US20180296677A1

公开(公告)日：2018-10-18

申请号：US16021193

申请日：2018-06-28

Applicant: Novartis AG

Inventor： Jeremy Lee Baryza ,  Rohan Eric John Beckwith ,  Keith Bowman ,  Crystal Byers ,  Tanzina Fazal ,  Gabriel Grant Gamber ,  Cameron Chuck-munn Lee ,  Ritesh Bhanudasji Tichkule ,  Chandra Vargeese ,  Shuangxi Wang ,  Laura Ellen West ,  Thomas Zabawa ,  Junping Zhao

IPC: A61K47/18 ,  C07C235/46 ,  A61K9/127 ,  C12N15/113 ,  C07D317/28 ,  C07D317/24 ,  C07D295/096 ,  C07D213/79 ,  C07D213/69 ,  C07D205/04 ,  C07C237/08 ,  C07C229/12 ,  C07C219/28 ,  C07C219/22 ,  C07C217/62 ,  C07C217/60 ,  C07C217/58 ,  A61K47/22

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.